COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02443883




Registration number
NCT02443883
Ethics application status
Date submitted
12/05/2015
Date registered
14/05/2015
Date last updated
29/06/2020

Titles & IDs
Public title
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
Scientific title
Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma
Secondary ID [1] 0 0
I4T-MC-JVDB
Secondary ID [2] 0 0
15608
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gastric Adenocarcinoma 0 0
Gastroesophageal Junction Adenocarcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Oesophageal (gullet)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ramucirumab

Experimental: Ramucirumab Regimen 1 - Standard dose of 8 milligram per kilogram (mg/kg) ramucirumab given intravenously (IV) on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.

Experimental: Ramucirumab Regimen 2 - Experimental dose of 12 mg/kg ramucirumab given IV on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.

Experimental: Ramucirumab Regimen 3 - Experimental dose of 6 mg/kg ramucirumab given IV on day 1, 8, 15 and 22 of each cycle (28-day cycle) until discontinuation criteria are met.

Experimental: Ramucirumab Regimen 4 - Experimental dose of 8 mg/kg ramucirumab given IV on day 1 and day 8 of each cycle (21-day cycle) until discontinuation criteria are met.


Treatment: Drugs: Ramucirumab
Administered IV

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab - The Cmin is the minimum observed serum concentration of ramucirumab.
Timepoint [1] 0 0
Day 29, 43, 71 and 85: predose
Secondary outcome [1] 0 0
Immunogenicity: Number of Participants With Anti-Ramucirumab Antibodies - Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. A treatment-emergent anti-drug antibodies (TEADA) sample was defined as: a post treatment sample with at least a 4-fold increase in titer from pre treatment sample; or 1:20 post treatment titer for participants that had no detectable ADA titer at baseline.
Timepoint [1] 0 0
Predose Cycle 1 Through Short Term Follow Up (Up to 5 Months)
Secondary outcome [2] 0 0
Rate of Progression Free Survival (PFS) at the First 6-Week Tumor Assessment - PFS defined as the time from first day of therapy to first evidence of disease progression per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) or death from any cause up to the first 6-week tumor assessment. Progressive Disease (PD) is at least 20% increase in sum of diameters of target lesions,taking as reference smallest sum on study and absolute increase of at least 5 mm.Appearance of 1 or more new lesions was also considered progression. Nontarget PD is unequivocal progression of existing nontarget lesions.Appearance of 1 or more new nontarget lesions was also considered PD.Participants with no baseline disease assessment: PFS time was censored at the randomization date,regardless of whether or not objectively determined disease progression or death has been observed.
Timepoint [2] 0 0
Baseline until the first 6-week tumor assessment

Eligibility
Key inclusion criteria
- The participant has a histopathologically or cytologically confirmed diagnosis of
gastric or gastroesophageal junction (GEJ).

- The participant has documented disease progression during or within 4 months after the
last dose of first-line chemotherapy for metastatic disease, or during or within 6
months after the last dose of neoadjuvant or adjuvant therapy.

- The participant received combination chemotherapy prior to disease progression.

- Prior chemotherapy regimens must include a platinum and/or a fluoropyrimidine
component and must not include a taxane or antiangiogenic agent.

- The participant has metastatic disease or locally advanced disease that is measurable
or nonmeasurable, but is evaluable disease by radiological imaging per Response
Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).

- Patients are eligible if they are considered not appropriate, for whatever reason, for
treatment with ramucirumab in combination with paclitaxel.

- The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of
0 or 1.

- The participant has adequate organ function, including:

- Total bilirubin 1.5 × the upper limit of institutional normal (ULN) and alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) 3 × ULN. If the liver
has tumor involvement, AST and ALT <5 × ULN are acceptable.

- Serum creatinine 1.5 × ULN or calculated creatinine clearance (per the
Cockcroft-Gault formula or equivalent and/or 24-hour urine collection) 60
milliliters/minute (mL/min).

- Urinary protein is <2+ on dipstick or routine urinalysis.

- Absolute neutrophil count 1.5 × 10^9/Liter (L), platelets 100 × 10^9/L, and
hemoglobin 9 g/deciliter (dL) (5.58 millimoles/Liter).

- International normalized ratio 1.5 × ULN or prothrombin time 5 seconds above ULN.

- Partial thromboplastin time 5 seconds above ULN.

- The participant has an estimated life expectancy of 12 weeks in the judgment of the
investigator.

- The participant, if female and of child-bearing potential, must have a negative serum
or urine pregnancy test within 7 days prior to randomization.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- The participant has squamous cell or undifferentiated gastric cancer.

- The participant is receiving chronic therapy with any of the following within 7 days
prior to randomization:

- Nonsteroidal anti-inflammatory agents (NSAIDs; such as indomethacin, ibuprofen,
naproxen, or similar agents), or

- Other anti-platelet agents (such as clopidogrel, ticlopidine, dipyridamole, or
anagrelide). Aspirin use at doses up to 325 milligrams (mg)/day is permitted.

- The participant received radiotherapy within 14 days prior to randomization.

- The participant received >1 line of prior therapy for the treatment of locally
advanced and unresectable or metastatic gastric or GEJ (Siewert Types I-III)
adenocarcinoma.

- The participant received previous treatment with agents targeting the vascular
endothelial growth factor (VEGF)/VEGF receptor 2 signaling pathway.

- The participant has documented brain metastases, leptomeningeal disease, or
uncontrolled spinal cord compression.

- The participant experienced any arterial thromboembolic event, including myocardial
infarction, unstable angina, cerebrovascular accident, or transient ischemic attack,
within 6 months prior to randomization.

- The participant has symptomatic congestive heart failure (New York Heart Association
II-IV) or symptomatic or poorly controlled cardiac arrhythmia.

- The participant has uncontrolled hypertension, as defined in Common Terminology
Criteria for Adverse Events (CTCAE) Version 4.0, prior to initiating study treatment,
despite antihypertensive intervention.

- The participant underwent major surgery within 28 days prior to randomization or
central venous access device placement within 7 days prior to randomization.

- The participant has a history of gastrointestinal perforation or fistula within 6
months prior to randomization.

- The participant has any condition (for example, psychological, geographical, or
medical) that does not permit compliance with the study and follow-up procedures or
suggests that the participant is, in the investigator's opinion, not an appropriate
candidate for the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Adelaide
Recruitment hospital [2] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Kingswood
Recruitment hospital [3] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Melbourne
Recruitment hospital [4] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Nedlands
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
2747 - Kingswood
Recruitment postcode(s) [3] 0 0
3144 - Melbourne
Recruitment postcode(s) [4] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
North Carolina
Country [4] 0 0
United States of America
State/province [4] 0 0
Oklahoma
Country [5] 0 0
United States of America
State/province [5] 0 0
Texas
Country [6] 0 0
Argentina
State/province [6] 0 0
Buenos Aires
Country [7] 0 0
Argentina
State/province [7] 0 0
Rosario
Country [8] 0 0
Argentina
State/province [8] 0 0
San Miguel de Tucumán
Country [9] 0 0
Argentina
State/province [9] 0 0
Viedma
Country [10] 0 0
France
State/province [10] 0 0
Brest
Country [11] 0 0
France
State/province [11] 0 0
Creteil
Country [12] 0 0
France
State/province [12] 0 0
Dijon
Country [13] 0 0
France
State/province [13] 0 0
Lyon
Country [14] 0 0
France
State/province [14] 0 0
Paris
Country [15] 0 0
Hungary
State/province [15] 0 0
Budapest
Country [16] 0 0
Hungary
State/province [16] 0 0
Szolnok
Country [17] 0 0
New Zealand
State/province [17] 0 0
Auckland
Country [18] 0 0
New Zealand
State/province [18] 0 0
Christchurch
Country [19] 0 0
Poland
State/province [19] 0 0
Gdansk
Country [20] 0 0
Poland
State/province [20] 0 0
Lodz
Country [21] 0 0
Poland
State/province [21] 0 0
Poznan
Country [22] 0 0
Poland
State/province [22] 0 0
Warszawa
Country [23] 0 0
Romania
State/province [23] 0 0
Baia Mare
Country [24] 0 0
Romania
State/province [24] 0 0
Cluj-Napoca
Country [25] 0 0
Romania
State/province [25] 0 0
Craiova
Country [26] 0 0
Russian Federation
State/province [26] 0 0
Arkhangelsk
Country [27] 0 0
Russian Federation
State/province [27] 0 0
Kursk
Country [28] 0 0
Russian Federation
State/province [28] 0 0
Moscow
Country [29] 0 0
Russian Federation
State/province [29] 0 0
St. Petersburg
Country [30] 0 0
Slovakia
State/province [30] 0 0
Bratislava
Country [31] 0 0
Slovakia
State/province [31] 0 0
Kosice
Country [32] 0 0
Turkey
State/province [32] 0 0
Edirne
Country [33] 0 0
Turkey
State/province [33] 0 0
Fatih
Country [34] 0 0
Turkey
State/province [34] 0 0
Pendik
Country [35] 0 0
Turkey
State/province [35] 0 0
Yüregir
Country [36] 0 0
United Kingdom
State/province [36] 0 0
Cardiff
Country [37] 0 0
United Kingdom
State/province [37] 0 0
Exeter
Country [38] 0 0
United Kingdom
State/province [38] 0 0
Leeds
Country [39] 0 0
United Kingdom
State/province [39] 0 0
Manchester
Country [40] 0 0
United Kingdom
State/province [40] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The main purpose of this study was to evaluate the safety and pharmacokinetics of
administering various dose regimens of ramucirumab in participants with advanced gastric
cancer whose disease has progressed during or following prior chemotherapy.
Trial website
https://clinicaltrials.gov/show/NCT02443883
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications